f Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Future Directions

References

1. Wang R. Chen Y. Shao X. Burden of skin cancer in older adults from 1990 to 2021 and modelled projection to 2050. JAMA Dermatol. 2025 161 7 715 722 10.1001/jamadermatol.2025.1276 40397469
   [Google Scholar]
2. Parker E.R. The influence of climate change on skin cancer incidence – A review of the evidence. Int. J. Womens Dermatol. 2021 7 1 17 27 10.1016/j.ijwd.2020.07.003 33537393
   [Google Scholar]
3. Hussain S. Mubeen I. Ullah N. Modern diagnostic imaging technique applications and risk factors in the medical field: A review. BioMed Res. Int. 2022 2022 1 5164970 10.1155/2022/5164970 35707373
   [Google Scholar]
4. Tawbi H.A. Schadendorf D. Lipson E.J. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 2022 386 1 24 34 10.1056/NEJMoa2109970 34986285
   [Google Scholar]
5. Wolchok J.D. Chiarion-Sileni V. Rutkowski P. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2025 392 1 11 22 10.1056/NEJMoa2407417 39282897
   [Google Scholar]
6. Gross N.D. Miller D.M. Khushalani N.I. Neoadjuvant cemiplimab for stage ii to iv cutaneous squamous-cell carcinoma. N. Engl. J. Med. 2022 387 17 1557 1568 10.1056/NEJMoa2209813 36094839
   [Google Scholar]
7. Grob J.J. Gonzalez R. Basset-Seguin N. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase ii trial (KEYNOTE-629). J. Clin. Oncol. 2020 38 25 2916 2925 10.1200/JCO.19.03054 32673170
   [Google Scholar]
8. Migden M.R. Rischin D. Schmults C.D. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 2018 379 4 341 351 10.1056/NEJMoa1805131 29863979
   [Google Scholar]
9. Rischin D. Porceddu S. Day F. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N. Engl. J. Med. 2025 393 8 774 785 10.1056/NEJMoa2502449 40454639
   [Google Scholar]
10. Abobaker M Govender M Choonara YE Non-surgical synergistic interventions for the treatment of skin cancer. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128298264240530061039 38910485
    [Google Scholar]
11. Shrestha S Cook CM Parekh J Mattei J A review on melanoma brain metastases. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128340742250118150157 40017253
    [Google Scholar]
12. Escobar GF Pauvels LSP Bakos RM Dermoscopic aspects of cutaneous melanoma and non-melanoma skin cancer. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128341374250310055950
    [Google Scholar]
13. Kreidieh F Wong MK New standards in the treatment of advanced metastatic melanoma: Immunotherapy and BRAF-targeted therapies as emerging paradigms. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128341628250519093548 40442907
    [Google Scholar]
14. Chedid M. Surgical excision margins in skin melanomas with breslow thickness greater than 2 mm: A systematic review and meta-analysis. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128341363250225095747 40108923
    [Google Scholar]
15. Chakraborty R Gohain RB Talukdar P Pre-clinical safety study of cold atmospheric plasma (CAP) produced by an inbuilt CAP device and ROS mediated apoptotic activity in human skin melanoma cells. Curr Pharm Des 2026 32 (4) 00 00 10.2174/0113816128335012250122221541 40070328
    [Google Scholar]